Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Conditions: Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease Interventions: Drug: TQJ230; Drug: Placebo Sponsors: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials